Cencora raises FY2024 adjusted EPS guidance to $13.60-$13.70; extends Evernorth supply deal through 2029

Cencora, Inc.

Adjusted diluted EPS for FY2024 raised to $13.60-$13.70 from prior $13.55-$13.65.
FY2025 adjusted operating income and EPS growth expected at bottom of long-term targets (5-8% and 8-12%).
FY2025 headwinds include COVID products and potential June 2025 loss of an oncology customer after its pending acquisition.
Extended pharmaceutical supply agreement with Evernorth Health Services for three additional years through September 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.